Polymorphism of the Serotonin TransporterImplications for the Use of Selective Serotonin Reuptake Inhibitors
作者:
Francis E. Lotrich,
Bruce G. Pollock,
Robert E. Ferrell,
期刊:
American Journal of PharmacoGenomics
(ADIS Available online 2001)
卷期:
Volume 1,
issue 3
页码: 153-164
ISSN:1175-2203
年代: 2001
出版商: ADIS
关键词: Genetic polymorphism;Pharmacogenetics;Psychiatric disorders;Serotonin reuptake inhibitors, pharmacodynamics
数据来源: ADIS
摘要:
Selective serotonin reuptake inhibitors (SSRIs) are used to treat a number of psychiatric disorders related to mood and anxiety, and variations in the serotonin transporter (5-HTT) gene may be involved in a number of these. A polymorphic site in the promoter region is associated with differences in5-HTTgene expression. Studies suggest that the short allele of the5-HTTpromoter (5-HTTPR) site can adversely influence the antidepressant response to SSRIs, and is associated with anxiety-related traits, depression, and impulsive disorders such as alcohol abuse. Several studies do not replicate these findings; potential confounding factors include age, gender, and population stratification. Other5-HTTpolymorphisms also exist. For example, individuals with the short allele of a variable number of tandem repeats (VNTR) polymorphism, located in the second intron, may have reduced responsiveness to SSRIs, and theSTin2.12allele at this site has been associated with bipolar disorder. Findings both supporting and inconsistent with these conclusions are reviewed. The clinical effects of the polymorphisms may be associated with effects on platelets, neural 5-HTT levels, and indices of serotonergic function.
点击下载:
PDF
(284KB)
返 回